Titan out-licenses Probuphine in Europe and other select territories

22 March 2018
titan-big

US drugmaker Titan Pharmaceuticals (Nasdaq: TTNP) has entered into a definitive asset purchase, supply and support agreement with privately-held Italian firm L Molteni & C, through which Molteni has acquired the European intellectual property related to Probuphine (buprenorphine).

This includes the Marketing Authorization Application (MAA) under review by the European Medicines Agency, and will have the exclusive right to commercialize the Titan supplied Probuphine product in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa.

Although buprenorphine had been available in pill or film form previously, in May 2016 the US Food and Drug Administration approved the first Probuphine implant for the maintenance treatment of opioid dependence, which was seen as a game-changer in the fight against opioid use disorder.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical